Author Index Volume 20 (2008)

The issue number is given in front of the page numbers.

Abematsu, Y., see Haga, Y. (4) 241–247

Agbabiaka, T.B., J. Savović, R. Harris and E. Ernst, The development of a tool to assess the quality of case reports of adverse events (3) 123–133

Appiah-Danquah, A., see Ofori-Adjei, D. (3) 113–122

Austin, D., An epidemiological analysis of the ‘autism as mercury poisoning’ hypothesis (3) 135–142

Bhansali, A., see Singh, N. (1,2) 45–50

Braslow, D., see Marks, D.H. (4) 231–240

Breggin, P.R., see Marks, D.H. (4) 231–240

Burashnikova, I.S., A.U. Ziganshin and L.E. Ziganshina, Attitudes to pharmaceutical promotion techniques among healthcare professionals in the Republic of Tatarstan, Russia (1,2) 57–71


Buttigieg, G.G., see Savona-Ventura, C. (3) 155–160

Cassar, O., see Buttigieg, G.G. (4) 223–230

Chen, Y., Z.A. Wu, C. Zhang and Z. Wu, Overview of safety monitoring of biologicals in China (4) 207–212

Collier, J., see Fuentes, H. (1,2) 83–89

Couper, M., see Ofori-Adjei, D. (3) 113–122

Crum, R.M., see Morrato, E.H. (3) 143–154

Curbow, B., see Morrato, E.H. (3) 143–154

Dhanaraj, E., see Singh, N. (1,2) 45–50

Dodoo, A.N.O., see Ofori-Adjei, D. (3) 113–122

Eckermann, E.J., see Whitstock, M.T. (3) 161–167

Ernst, E., see Agbabiaka, T.B. (3) 123–133

Fan-Dian, Z., see Yue, W. (1,2) 51–56

Feinleib, M., see Morrato, E.H. (3) 143–154

Fuentes, H., J. Collier, M. Sinnott and M. Whitby, “Scalpel safety”: Modeling the effectiveness of different safety devices’ ability to reduce scalpel blade injuries (1,2) 83–89

Fukano, K., see Haga, Y. (4) 241–247

Grima, S., see Savona-Ventura, C. (3) 155–160

Hama, R., Fatal neuropsychiatric adverse reactions to oseltamivir: Case series and overview of causal relationships (1,2) 5–36
Harris, R., see Agbabiaka, T.B. (3) 123–133
Hou-Ming, X., see Yue, W. (1,2) 51–56
Huang, Q., Clinical risk management, medical negligence prevention and the law: A review (4) 185–197
Huang, Q., Clinical risk analysis under the law of negligence: A new approach to medical negligence prevention (4) 199–205
Jimmy, B., see Jose, J. (3) 169–180
Jose, J., P.G.M. Rao and B. Jimmy, Adverse drug reactions to fluoroquinolone antibiotics – Analysis of reports received in a tertiary care hospital (3) 169–180
Jureidini, J.N., L.B. McHenry and P.R. Mansfield, Clinical trials and drug promotion: Selective reporting of study 329 (1,2) 73–81
Kapp, M.B., Legal issues in dementia (1,2) 91–103
Kawano, M., see Haga, Y. (4) 241–247
Koga, T., see Haga, Y. (4) 241–247
Kruszewski, S.P. and R.P. Paczynski, Atypical antipsychotic agents for the schizophrenia pro-drome: Not a clear first choice (1,2) 37–44
Mansfield, P.R., see Jureidini, J.N. (1,2) 73–81
Marjoribanks, T.K., see Whitstock, M.T. (3) 161–167
Marks, D.H., P.R. Breggin and D. Braslow, Homicidal ideation causally related to therapeutic medications (4) 231–240
Matoba, K., see Haga, Y. (4) 241–247
Matsukura, S., see Haga, Y. (4) 241–247
McHenry, L.B., see Jureidini, J.N. (1,2) 73–81
Ming, L., see Yue, W. (1,2) 51–56
Nagamatsu, Y., see Haga, Y. (4) 241–247
Nowels, C., see Morrato, E.H. (3) 143–154
Ofori-Adjei, D., A.N.O. Dodoo, A. Appiah-Danquah and M. Couper, A review of the safety of niclosamide, pyrantel, triclabendazole and oxamniquine (3) 113–122
Paczynski, R.P., see Kruszewski, S.P. (1,2) 37–44
Pearce, C.M., see Whitstock, M.T. (3) 161–167
Rao, P.G.M., see Jose, J. (3) 169–180
Savona-Ventura, C., G.G. Buttigieg, S. Grima and M. Vella, Anthropomorphic characteristics as obstetric risk determinants (3) 155–160
Savona-Ventura, C., see Buttigieg, G.G. (4) 223–230
Savović, J., see Agbabiaka, T.B. (3) 123–133
Sawalha, A.F., Self-medication with antibiotics: A study in Palestine (4) 213–222
Singh, N., E. Dhanaraj, P. Tiwari and A. Bhansali, Attainment of target blood pressure and patterns of antihypertensive therapy in type 2 diabetic hypertensive Asian Indians (1,2) 45–50
Sinnott, M., see Fuentes, H. (1,2) 83–89
Tiwari, P., see Singh, N. (1,2) 45–50
Tonai, T., see Haga, Y. (4) 241–247

Vella, K., see Buttigieg, G.G. (4) 223–230
Vella, M., see Savona-Ventura, C. (3) 155–160

Whitby, M., see Fuentes, H. (1,2) 83–89
Whitstock, M.T., E.J. Eckermann, T.K. Marjoribanks and C.M. Pearce, Pharmaceutical economics and politics vs. patient safety: Lumiracoxib in Australia (3) 161–167
Wu, Z., see Chen, Y. (4) 207–212
Wu, Z.A., see Chen, Y. (4) 207–212

Yamanouchi, T., see Haga, Y. (4) 241–247
Yan, G., see Yue, W. (1,2) 51–56
Yoshidomi, K., see Haga, Y. (4) 241–247
Yue, W., X. Hou-Ming, L. Ming, G. Yan, Y. Bo-Yang and Z. Fan-Dian, Regional pharmacovigilance practice in China (1,2) 51–56

Zhang, C., see Chen, Y. (4) 207–212
Ziganshin, A.U., see Burashnikova, I.S. (1,2) 57–71
Ziganshina, L.E., see Burashnikova, I.S. (1,2) 57–71